PriceTargets.com logo

Kura Oncology - KURA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.83
  • Forecasted Upside: 67.44%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$17.22 As of 10/30/2024 03:56 PM ET
▼ -0.14 (-0.81%)

This chart shows the closing price for KURA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kura Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KURA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KURA

Analyst Price Target is $28.83
▲ +67.44% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $28.83, with a high forecast of $37.00 and a low forecast of $19.00. The average price target represents a 67.44% upside from the last price of $17.22.

This chart shows the closing price for KURA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Kura Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
10/24/2024UBS GroupInitiated CoverageBuy$27.00
10/22/2024Lifesci CapitalUpgradeStrong-Buy
10/14/2024Stifel NicolausDowngradeBuy ➝ Hold$26.00 ➝ $19.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/12/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$32.00 ➝ $32.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
8/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/9/2024WedbushReiterated RatingOutperform ➝ Outperform$37.00 ➝ $37.00
8/9/2024Stifel NicolausLower TargetBuy ➝ Buy$28.00 ➝ $26.00
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
6/18/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$32.00 ➝ $32.00
5/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$32.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
5/6/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$32.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
5/3/2024WedbushReiterated RatingOutperform ➝ Outperform$37.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
2/28/2024WedbushReiterated RatingOutperform ➝ Outperform$37.00
1/31/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $32.00
12/22/2023MizuhoInitiated CoverageBuy$26.00
12/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
11/3/2023WedbushLower TargetOutperform ➝ Outperform$40.00 ➝ $37.00
10/18/2023WedbushReiterated RatingOutperform ➝ Outperform$40.00
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
8/11/2023Bank of AmericaInitiated CoverageBuy$31.00
7/27/2023ScotiabankInitiated CoverageSector Perform$10.50
7/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
7/14/2023Maxim GroupUpgradeHold ➝ Buy
6/12/2023Stifel NicolausBoost Target$24.00 ➝ $25.00
5/16/2023BTIG ResearchInitiated CoverageBuy$31.00
5/11/2023Stifel NicolausLower Target$25.00 ➝ $24.00
4/17/2023JMP SecuritiesReiterated RatingMarket Outperform$22.00
2/24/2023HC WainwrightReiterated RatingBuy$32.00
2/10/2023HC WainwrightReiterated RatingBuy$32.00
1/30/2023Stifel NicolausInitiated CoverageBuy$25.00
9/29/2022Maxim GroupDowngradeBuy ➝ Hold
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
8/4/2022WedbushReiterated RatingOutperform$40.00
7/13/2022Credit Suisse GroupBoost TargetOutperform$27.00 ➝ $29.00
7/12/2022Cantor FitzgeraldInitiated CoverageOverweight$30.00
5/16/2022Dawson JamesDowngradeBuy ➝ Neutral
2/25/2022Credit Suisse GroupBoost TargetOutperform$25.00 ➝ $27.00
2/25/2022Leerink PartnersLower TargetOutperform$41.00 ➝ $28.00
2/15/2022Jefferies Financial GroupInitiated CoverageBuy$35.00
1/20/2022HC WainwrightLower TargetBuy$10,500.00 ➝ $5,250.00
1/7/2022BMO Capital MarketsBoost Target$70.00 ➝ $80.00
12/15/2021JMP SecuritiesReiterated RatingBuy$26.00
11/29/2021JMP SecuritiesReiterated RatingBuy$25.00
11/26/2021Credit Suisse GroupLower TargetHold ➝ Outperform$40.00 ➝ $21.00
11/24/2021HC WainwrightLower TargetHold ➝ Buy$43.00 ➝ $32.00
11/8/2021WedbushReiterated RatingOutperform
10/8/2021Maxim GroupInitiated CoverageBuy$5,250.00
9/30/2021AegisLower TargetBuy$12,250.00 ➝ $8,750.00
9/28/2021HC WainwrightInitiated CoverageBuy$10,500.00
8/6/2021Credit Suisse GroupLower TargetOutperform$42.00 ➝ $40.00
8/6/2021Leerink PartnersBoost TargetOutperform$40.00 ➝ $41.00
7/2/2021Maxim GroupReiterated RatingBuy$10,500.00
5/5/2021Credit Suisse GroupInitiated CoverageOutperform$42.00
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$42.00
2/26/2021Leerink PartnersLower TargetOutperform$42.00 ➝ $40.00
2/24/2021HC WainwrightLower TargetBuy$45.00 ➝ $43.00
2/3/2021AegisBoost TargetBuy$10,500.00 ➝ $12,250.00
12/7/2020WedbushBoost TargetOutperform$44.00 ➝ $56.00
12/7/2020BarclaysBoost TargetOverweight$40.00 ➝ $47.00
12/7/2020HC WainwrightBoost TargetBuy$40.00 ➝ $45.00
12/2/2020Stifel NicolausInitiated CoverageBuy$45.00
11/20/2020Maxim GroupInitiated CoverageBuy$5,250.00
11/5/2020Piper SandlerDowngradeOverweight ➝ Neutral$25.00 ➝ $34.00
10/26/2020JMP SecuritiesBoost Target$22.00 ➝ $33.00
10/12/2020HC WainwrightBoost TargetBuy$22.00 ➝ $40.00
10/8/2020CSFBBoost TargetOutperform$27.00 ➝ $43.00
10/8/2020Credit Suisse GroupBoost TargetOutperform$27.00 ➝ $43.00
10/1/2020AegisReiterated RatingBuy$10,500.00
9/30/2020BarclaysBoost TargetPositive ➝ Overweight$32.00 ➝ $37.00
9/14/2020AegisInitiated CoverageBuy$10,500.00
8/31/2020BarclaysBoost TargetOverweight$24.00 ➝ $32.00
8/16/2020Brookline Capital ManagementReiterated RatingBuy
7/28/2020Maxim GroupReiterated RatingBuy$3,500.00
7/7/2020Credit Suisse GroupInitiated CoverageOutperform$27.00
6/23/2020Maxim GroupInitiated CoverageBuy$3,500.00
6/6/2020Maxim GroupInitiated CoverageBuy$3,500.00
5/31/2020OppenheimerInitiated CoverageBuy$23.00 ➝ $27.00
5/29/2020HC WainwrightReiterated RatingBuy$22.00
5/19/2020Deutsche Bank AktiengesellschaftLower TargetBuy$28.00 ➝ $24.00
5/14/2020Maxim GroupReiterated RatingBuy$3,500.00
5/6/2020WedbushLower TargetOutperform$30.00 ➝ $28.00
5/5/2020OppenheimerLower TargetOutperform$27.00 ➝ $23.00
5/5/2020HC WainwrightLower TargetBuy$29.00 ➝ $22.00
5/4/2020BarclaysInitiated CoverageOverweight$24.00
2/26/2020Piper SandlerLower Target$32.00 ➝ $30.00
12/16/2019HC WainwrightReiterated RatingBuy$29.00
12/6/2019CowenReiterated RatingBuy
11/15/2019Maxim GroupReiterated RatingBuy
11/6/2019CowenReiterated RatingBuy
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/3/2024
  • 8 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/3/2024
  • 8 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 8 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 8 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Kura Oncology logo
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $17.22
Low: $17.10
High: $17.58

50 Day Range

MA: $19.24
Low: $17.02
High: $21.08

52 Week Range

Now: $17.22
Low: $7.92
High: $24.17

Volume

117,607 shs

Average Volume

893,334 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Kura Oncology?

The following sell-side analysts have issued stock ratings on Kura Oncology in the last twelve months: Cantor Fitzgerald, HC Wainwright, JMP Securities, Lifesci Capital, Mizuho, Stifel Nicolaus, StockNews.com, UBS Group AG, and Wedbush.
View the latest analyst ratings for KURA.

What is the current price target for Kura Oncology?

6 Wall Street analysts have set twelve-month price targets for Kura Oncology in the last year. Their average twelve-month price target is $28.83, suggesting a possible upside of 67.4%. Wedbush has the highest price target set, predicting KURA will reach $37.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $19.00 for Kura Oncology in the next year.
View the latest price targets for KURA.

What is the current consensus analyst rating for Kura Oncology?

Kura Oncology currently has 1 hold rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KURA will outperform the market and that investors should add to their positions of Kura Oncology.
View the latest ratings for KURA.

What other companies compete with Kura Oncology?

Other companies that are similar to Kura Oncology include Xencor, IGM Biosciences, Zymeworks, Ironwood Pharmaceuticals and Aimmune Therapeutics. Learn More about companies similar to Kura Oncology.

How do I contact Kura Oncology's investor relations team?

Kura Oncology's physical mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company's listed phone number is (858) 500-8800 and its investor relations email address is [email protected]. The official website for Kura Oncology is www.kuraoncology.com. Learn More about contacing Kura Oncology investor relations.